Search the GHTC website

Global health R&D delivers for Tennessee

US government investment in global health R&D has delivered

Amount
$237.8 million
to Tennessee research institutions
Jobs
3,100+ new jobs
for Tennessee
Tennessee's top USG-funded global health R&D institutions

Tennessee's top USG-funded global health R&D institutions

Vanderbilt University
$144.4 million
St. Jude Children's Research Hospital
$52.9 million
The University of Tennessee Health Science Center
$22.4 million
Meharry Medical College
$10.8 million
IDBiologics
$4.6 million
Micronics Inc.
$1 million
Immuno Technologies
$693 thousand
Microbial Novoteqs Inc.*
$611 thousand
Rhodes College
$307 thousand

Tennessee's top areas of global health R&D by USG funding

15.3%
COVID-19
2.5%
Other coronaviruses (including MERS, SARS)
6.1%
Flioviral diseases (including Ebola, Marburg)
22.5%
HIV/AIDS
6.3%
Malaria
6.9%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
3.9%
Rheumatic fever
20.3%
Tuberculosis
5%
Zika
11.3%
Other
Bacterial pneumonia & meningitis
Chikungunya
Cryptococcal meningitis
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Leptospirosis
Mpox
Multi-disease/health area R&D
Reproductive health
Salmonella infections
Global health R&D at work in Tennessee

Duke University scientists are working to advance a pan-coronavirus vaccine that could protect against multiple coronaviruses. Within months of the emergence of the COVID-19 pandemic, Duke researchers developed a candidate vaccine and validated its proof of concept in preclinical studies. Now, the Duke Human Vaccine Institute, with support from the US National Institutes of Health, is manufacturing doses for upcoming human clinical trials. Given coronaviruses are a family of viruses with a high likelihood of spurring future epidemics and pandemics, such a vaccine would be a powerful new tool for improving health preparedness.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: US Department of State